Alma Cruz, MD
Allergy · Miami Lakes, FLNPI 1699181966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,050, 2.9 times the $700 reported in 2019.
Across 257 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$993
- AstraZeneca$939
- Novartis$396
- Optinose US, Inc.$253
- plus $1K from 21 others
What the payments were for
- Grants$4006%
- Food & beverage$5,68691%
- Education$1873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 84 | $1,334 |
| Regeneron Healthcare Solutions, Inc. | 33 | $1,048 |
| Sanofi | 22 | $993 |
| AstraZeneca | 38 | $939 |
| Novartis | 10 | $396 |
| Optinose US, Inc. | 12 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $192 |
| Amgen | 5 | $139 |
| Genentech USA, Inc. | 2 | $123 |
| Octapharma USA, Inc. | 2 | $116 |
| CSL Behring | 5 | $116 |
| Grifols USA, LLC | 5 | $112 |
| Organon | 10 | $71 |
| Alk-abello, Inc | 4 | $61 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $54 |
| Pfizer | 2 | $41 |
| Phadia US Inc. | 1 | $39 |
| Lilly USA, LLC | 2 | $37 |
| Kaleo, Inc. | 2 | $35 |
| Greer Laboratories, Inc. | 1 | $28 |
| UCB, Inc. | 1 | $28 |
| GC Biopharma USA, Inc. | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $23 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,273 in reported general payments places this provider in the 70th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 15 | $55,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $42,654 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $13,051 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,534 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,230 |
| DuleraMometasone/Formoterol | 12 | $4,119 |
| Azelastine Hcl | 109 | $3,131 |
| Epinephrine | 14 | $2,426 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,110 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,731 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,326 |
| Ventolin HfaAlbuterol Sulfate | 16 | $817 |
| Fluticasone Propionate | 37 | $654 |
| Famotidine | 31 | $546 |
| Levocetirizine Dihydrochloride | 32 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,334 | $48,88481 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $939 | $21,58548 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 56 allergy providers in Florida.
Other allergy in Miami Lakes
- Stephania LairetMiami Lakes$4K
- Miguel LanzCoral Gables$778K
- Brett StanalandNaples$575K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Hugh WindomSarasota$37K
- Patrick de MarcoOrange Park$23K
- Mark MinorMelbourne$21K
- Alan KoterbaNorth Palm Beach$16K
- Brian WilsonTallahassee$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.